SRI International received support from the NCI thus gaining access to the drug development resources of the Developmental Therapeutics Program. The company will use these assets to further the preclinical development of its drug to treat advanced cancers. SR16388, a novel antiangiogenic drug, is being investigated for the treatment of multiple tumor types, including metastatic prostate cancer.
"SR16388 is the third SRI drug candidate to be awarded development support from the National Cancer Institute," points out Nathan Collins, Ph.D., executive director of drug discovery in SRI's biosciences division.
The contract was won through NCI’s Rapid Access to Intervention Development, a peer-reviewed competitive award program designed to assist translation of novel anticancer therapeutics to the clinic.